JPWO2021133653A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021133653A5
JPWO2021133653A5 JP2022538737A JP2022538737A JPWO2021133653A5 JP WO2021133653 A5 JPWO2021133653 A5 JP WO2021133653A5 JP 2022538737 A JP2022538737 A JP 2022538737A JP 2022538737 A JP2022538737 A JP 2022538737A JP WO2021133653 A5 JPWO2021133653 A5 JP WO2021133653A5
Authority
JP
Japan
Prior art keywords
cancer
composition
cdr
domain
lag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507848A (ja
JP2023507848A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065873 external-priority patent/WO2021133653A1/en
Publication of JP2023507848A publication Critical patent/JP2023507848A/ja
Publication of JPWO2021133653A5 publication Critical patent/JPWO2021133653A5/ja
Publication of JP2023507848A5 publication Critical patent/JP2023507848A5/ja
Priority to JP2025154757A priority Critical patent/JP2026001028A/ja
Pending legal-status Critical Current

Links

JP2022538737A 2019-12-23 2020-12-18 癌の治療のための療法 Pending JP2023507848A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025154757A JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962952878P 2019-12-23 2019-12-23
US201962952859P 2019-12-23 2019-12-23
US62/952,878 2019-12-23
US62/952,859 2019-12-23
US202063019857P 2020-05-04 2020-05-04
US63/019,857 2020-05-04
US202063021556P 2020-05-07 2020-05-07
US63/021,556 2020-05-07
US202063031453P 2020-05-28 2020-05-28
US63/031,453 2020-05-28
US202063123581P 2020-12-10 2020-12-10
US63/123,581 2020-12-10
PCT/US2020/065873 WO2021133653A1 (en) 2019-12-23 2020-12-18 Therapy for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025154757A Division JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Publications (3)

Publication Number Publication Date
JP2023507848A JP2023507848A (ja) 2023-02-27
JPWO2021133653A5 true JPWO2021133653A5 (https=) 2023-12-21
JP2023507848A5 JP2023507848A5 (https=) 2023-12-21

Family

ID=76575359

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538737A Pending JP2023507848A (ja) 2019-12-23 2020-12-18 癌の治療のための療法
JP2025154757A Pending JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025154757A Pending JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Country Status (13)

Country Link
US (1) US20230056230A1 (https=)
EP (1) EP4081248A4 (https=)
JP (2) JP2023507848A (https=)
KR (1) KR20220119694A (https=)
CN (1) CN114901306A (https=)
AU (1) AU2020412595A1 (https=)
BR (1) BR112022012437A2 (https=)
CA (1) CA3165839A1 (https=)
IL (1) IL294207A (https=)
MX (1) MX2022007790A (https=)
TW (1) TW202138387A (https=)
WO (1) WO2021133653A1 (https=)
ZA (1) ZA202206743B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4106813A4 (en) * 2020-02-21 2024-03-27 MacroGenics, Inc. CD137 BINDING MOLECULES AND THEIR USES
WO2022087402A1 (en) * 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
EP4363449A2 (en) * 2021-07-02 2024-05-08 Genentech, Inc. Methods and compositions for treating cancer
AU2022317820A1 (en) * 2021-07-28 2023-12-14 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
CA3233205A1 (en) * 2021-09-29 2023-04-06 Yu Xia Anti-lag3 antibody, pharmaceutical composition and use
WO2023066322A1 (zh) * 2021-10-21 2023-04-27 杭州阿诺生物医药科技有限公司 一种融合多肽及其用途
WO2024051223A1 (zh) * 2022-09-09 2024-03-14 中山康方生物医药有限公司 药物组合及用途
WO2024163009A1 (en) * 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
TW202436339A (zh) * 2023-01-31 2024-09-16 瑞士商赫孚孟拉羅股份公司 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5998060B2 (ja) * 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
SG11201601763SA (en) * 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
TWI693232B (zh) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2017019846A1 (en) * 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
AU2016307955A1 (en) * 2015-08-17 2018-03-08 Macrogenics, Inc. Bispecific monovalent diabodies that are capable of binding B7-H3 and CD3, and uses thereof
US10954301B2 (en) * 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
TWI781098B (zh) * 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
MX2018014950A (es) * 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
KR102664891B1 (ko) * 2016-06-20 2024-05-13 에프-스타 테라퓨틱스 리미티드 Pd-l1 및 lag-3에 결합하는 결합 분자
CN111315776A (zh) * 2017-03-29 2020-06-19 葛莱高托普有限公司 Pd-l1和ta-muc1抗体
TWI690538B (zh) * 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
EP3630179A2 (en) * 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019179422A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/lag-3 antibody molecules

Similar Documents

Publication Publication Date Title
Reichert et al. The future of antibodies as cancer drugs
JP6953612B2 (ja) チェックポイントインヒビター二重特異性抗体
JP7720785B2 (ja) 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
JP2020501531A5 (https=)
CN117024593A (zh) 抗SIRPα抗体
HRP20241289T1 (hr) Molekule za vezanje pd-1 i postupci za njihovu uporabu
JP2018524394A5 (https=)
CA3020864A1 (en) Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
JP2018507188A5 (https=)
JP2021510736A5 (https=)
JPWO2019224718A5 (https=)
JP2013529059A5 (https=)
JP2023512774A (ja) 抗ｒｏｒ１抗体および組成物
JP2021525544A5 (https=)
CA2872226A1 (en) Humanized pan-her antibody compositions
CN114901306A (zh) 用于治疗癌症的疗法
JP2020522473A5 (https=)
EP4588524A2 (en) Anti-tigit and anti-pvrig in monotherapy and combination treatments
Dhimolea et al. World bispecific antibody summit, September 27–28, 2011, Boston, MA
JP2022521305A (ja) 抗ｐｄ－ｌ１抗体及びその使用
JPWO2021133653A5 (https=)
MX2015000730A (es) Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja.
CN109071671B (zh) Erbb2靶向抗体
WO2021058735A1 (en) Cancer treatment with anti-met antibody compositions
EP3962525A1 (en) Combination of her2 antibodies